JNJ
JOHNSON & JOHNSONC5015-min delayed · EOD close266.34 +0.29% upas of 2026-09-14mkt cap $641B
Pharmaceutical Preparations · SIC 2834 · CIK 0000200406
Quality score
50/100
C
Growth46
Business quality70
Financial health30
Valuation54
Computed from filed fundamentals against fixed reference bands. Not a recommendation, and not a peer percentile.
The read
Mixed picture
Uneven
Strongest on business quality (70), weakest on financial health (30). The composite is the mean of the sub-scores that could be computed. All inputs were available in the filings.
Revenue growth
11.8%
year over year
Earnings growth
14.4%
year over year
Gross margin